PATIENTS

Keep track of your cancer
and treatment results with
Guardant Complete.

Guardant Complete is a range of liquid and tissue tests for patients with early-stage and advanced-stage cancer. The results of each test enable your doctor to:

  • Monitor your
    cancer status.1
  • Make treatment decisions.2

  • See if your treatment
    is working or not.3

Sign in to your myGuardant Portal

Explore Guardant Complete testing options.

Guardant Reveal™1,4-6

SUITABLE FOR
Stage II or III colorectal, breast, or lung cancer
LIQUID TEST
checked
USES CANCER DNA FOR DETECTION
checked
INFORMS TREATMENT DECISIONS
checked
MEDICARE COVERAGE
Stage II or III colorectal cancer patients only
SWIPE TO REVEAL FULL TABLE
FDA-Approved

Guardant360® CDx2,7

Guardant360®8

Guardant360 TissueNext™9

Guardant360 Response™3,10

SUITABLE FOR ANY SOLID TUMOR CANCER
checked
checked
checked
checked
LIQUID TEST
checked
checked
N/A
checked
USES CANCER DNA FOR DETECTION
checked
checked
checked
checked
INFORMS TREATMENT DECISIONS
checked
checked
checked
checked
MEDICARE COVERAGE
checked
checked
checked
N/A
Explore product
Explore product
Explore product
Explore product

Guardant Reveal™1,4-6

SUITABLE FOR
Stage II or III colorectal, breast, or lung cancer
LIQUID TEST
checked
USES CANCER DNA FOR DETECTION
checked
INFORMS TREATMENT DECISIONS
checked
MEDICARE COVERAGE
Stage II or III colorectal cancer patients only
SWIPE TO REVEAL FULL TABLE
FDA-Approved

Guardant360® CDx2,7

Guardant360®8

Guardant360 TissueNext™9

Guardant360 Response™3,10

SUITABLE FOR ANY SOLID TUMOR CANCER
checked
checked
checked
checked
LIQUID TEST
checked
checked
N/A
checked
USES CANCER DNA FOR DETECTION
checked
checked
checked
checked
INFORMS TREATMENT DECISIONS
checked
checked
checked
checked
MEDICARE COVERAGE
checked
checked
checked
N/A
Explore product
Explore product
Explore product
Explore product

Important Note: The Guardant Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 are Laboratory Developed Tests (LDTs). These tests have not been cleared or approved by the US FDA.

*Turnaround times are most current best estimates based on actual sample processing times.

A liquid test is a minimally invasive blood draw that enables your doctor to frequently track your cancer status and quickly make treatment decisions.1,11

GUARDANT ACCESS & SUPPORT

GUARDANT ACCESS & SUPPORT

Visit your myGuardant patient profile.

Get full access to each of your Guardant testing reports as soon as they’re
available—so you can see what your doctor sees.

Go to myGuardant portal

To activate your account, visit patients.guardanthealth.com.

Guardant Access helps
manage the billing process.

To enroll in the Guardant Access program, review and sign the test order
form provided by your doctor.

  • Checks your eligibility for financial assistance if needed.

  • Helps manage the billing process with your insurance company.

  • Handles your billing questions related
    to Guardant Complete.

  • Makes every attempt to contact you if your expected out-of-pocket expense exceeds $100.

Contact Guardant Complete Patient Support.

Reach us via phone at 855.698.8887 or via email at guardantaccess@guardanthealth.com.

References: 1. Backgrounder: Guardant Reveal™ Liquid Biopsy Test. Guardant Health, Inc. Redwood City, CA. 2. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021. 3. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 4. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 5. Janni W, Huober J, Braun T, et al. Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Poster presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; Philadelphia, PA. Accessed June 29, 2023. https://doi.org/10.1158/1538-7445.AM2022-3403 6. Nagasaka M, Uddin MH, Al-Hallak MN, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20(1):82. doi:10.1186/s12943-021-01371-1 7. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7 2020. Accessed June 29, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 8. Guardant360® Assay Specifications. Guardant Health, Inc. Redwood City, CA. 9. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Redwood City, CA. 10. Guardant360® Response: Guide to Ordering Guardant360 Response. Guardant Health, Inc. Redwood City, CA. 11. Cui W, Milner-Watts C, O'Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012